戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  every 2 weeks for 12 weeks with concomitant topical glucocorticoids.
2  children who fail to respond as expected to topical glucocorticoids.
3 e gloves) and applying emollients and potent topical glucocorticoids.
4 ere atopic dermatitis despite treatment with topical glucocorticoids and calcineurin inhibitors.
5 s shown that over 80% of patients prescribed topical glucocorticoids are fearful of side effects and
6    We investigated whether cytokines and the topical glucocorticoid budesonide differentially regulat
7 lysis of human skin transcriptome induced by topical glucocorticoid clobetasol propionate (CBP) in he
8 similar magnitude to that seen with a potent topical glucocorticoid, clobetasol.
9                                              Topical glucocorticoids continue to be well tolerated, e
10                                   The potent topical glucocorticoid fluticasone propionate significan
11 d healing are the recognized side effects of topical glucocorticoid (GC) therapy.
12 in one 12-week trial and in combination with topical glucocorticoids in another 4-week study.
13 how in vitro and in vivo that treatment with topical glucocorticoids leads to rapid restoration of gl
14  on ABT, treatment led to control of CAU and topical glucocorticoids tapered to <=2 drops/d with no n
15                                              Topical glucocorticoid therapy, with or without concurre
16  monograph reviews recent studies, examining topical glucocorticoid use in children.
17 Risk of cataract development associated with topical glucocorticoid use is better defined.
18 corticoids used less than half the amount of topical glucocorticoids used by those who received place
19 , as compared with 50% of those who received topical glucocorticoids with placebo injection, met the